| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,¶
*
Swim Across America Laboratory, Departments of
Surgery,
Medicine, and
§
Biostatistics and Epidemiology, and
¶
Sloan-Kettering Division, Cornell University Graduate School of Medical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Melanosomal membrane proteins are frequently recognized by the immune system of patients with melanoma and vitiligo. Melanosomal glycoproteins are transported to melanosomes by a dileucine-based melanosomal transport signal (MTS). To investigate whether this sorting signal could be involved in presentation of melanosome membrane proteins to the immune system, we devised a fusion construct containing the MTS from the mouse brown locus product gp75/tyrosinase-related protein-1 and full-length OVA as a reporter Ag. The fusion protein was expressed as an intracellular membrane protein, sorted to the endocytic pathway, processed, and presented by class II MHC molecules. DNA immunization with this construct elicited CD4+ T cell proliferative responses in vivo. Ag presentation and T cell responses in vitro and in vivo required a functional MTS. Mutations of either the upstream leucine in MTS or elimination of the entire MTS negated in vitro Ag presentation and in vivo T cell responses. In a mouse melanoma model, DNA immunization with MTS constructs protected mice from tumor challenge in a CD4+ T cell-dependent manner, but complete deletion of MTS decreased tumor rejection. Therefore, MTS can target epitopes to the endocytic pathway leading to presentation by class II MHC molecules to helper T cells.
This article has been cited by other articles:
|
|
 |
|
  V. Bradley, E. H. Kemp, C. Dickinson, T. Key, P. Gibbs, and M. R. Clatworthy Vitiligo following a combined liver-kidney transplant Nephrol. Dial. Transplant., February 1, 2009; 24(2): 686 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lepage and R. Lapointe Melanosomal Targeting Sequences from gp100 Are Essential for MHC Class II-Restricted Endogenous Epitope Presentation and Mobilization to Endosomal Compartments Cancer Res., February 15, 2006; 66(4): 2423 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Theos, D. Tenza, J. A. Martina, I. Hurbain, A. A. Peden, E. V. Sviderskaya, A. Stewart, M. S. Robinson, D. C. Bennett, D. F. Cutler, et al. Functions of Adaptor Protein (AP)-3 and AP-1 in Tyrosinase Sorting from Endosomes to Melanosomes Mol. Biol. Cell, November 1, 2005; 16(11): 5356 - 5372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Mora, J. LaVoy, M. McKean, A. Stecenko, K. L. Brigham, R. Parker, and M. Rojas Prevention of NF-{kappa}B activation in vivo by a cell-permeable NF-{kappa}B inhibitor peptide Am J Physiol Lung Cell Mol Physiol, October 1, 2005; 289(4): L536 - L544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, P. Chaux, V. Stroobant, A. M. M. Eggermont, J. Corthals, B. Maillere, K. Thielemans, M. Marchand, T. Boon, and P. van der Bruggen A MAGE-3 Peptide Presented by HLA-DR1 to CD4+ T Cells That Were Isolated from a Melanoma Patient Vaccinated with a MAGE-3 Protein J. Immunol., July 1, 2003; 171(1): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Novellino, N. Renkvist, F. Rini, A. Mazzocchi, L. Rivoltini, A. Greco, P. Deho, P. Squarcina, P. F. Robbins, G. Parmiani, et al. Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase {kappa} as a Novel, Class II HLA-Restricted Melanoma Antigen J. Immunol., June 15, 2003; 170(12): 6363 - 6370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Bergman, J. McKnight, A. Novosad, S. Charney, J. Farrelly, D. Craft, M. Wulderk, Y. Jeffers, M. Sadelain, A. E. Hohenhaus, et al. Long-Term Survival of Dogs with Advanced Malignant Melanoma after DNA Vaccination with Xenogeneic Human Tyrosinase: A Phase I Trial Clin. Cancer Res., April 1, 2003; 9(4): 1284 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Robbins, M. El-Gamil, Y. F. Li, G. Zeng, M. Dudley, and S. A. Rosenberg Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma J. Immunol., November 15, 2002; 169(10): 6036 - 6047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Touloukian, W. W. Leitner, P. F. Robbins, S. A. Rosenberg, and N. P. Restifo Mining the Melanosome for Tumor Vaccine Targets: P.polypeptide Is a Novel Tumor-associated Antigen Cancer Res., November 1, 2001; 61(22): 8100 - 8104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lapointe, R. E. Royal, M. E. Reeves, I. Altomare, P. F. Robbins, and P. Hwu Retrovirally Transduced Human Dendritic Cells Can Generate T Cells Recognizing Multiple MHC Class I and Class II Epitopes from the Melanoma Antigen Glycoprotein 100 J. Immunol., October 15, 2001; 167(8): 4758 - 4764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Shedlock and D. B. Weiner DNA vaccination: antigen presentation and the induction of immunity J. Leukoc. Biol., December 1, 2000; 68(6): 793 - 806. [Abstract] [Full Text]
|
|
|
|
|
|
E. S. Schultz, B. Lethé, C. L. Cambiaso, J. Van Snick, P. Chaux, J. Corthals, C. Heirman, K. Thielemans, T. Boon, and P. van der Bruggen A MAGE-A3 Peptide Presented by HLA-DP4 Is Recognized on Tumor Cells by CD4+ Cytolytic T Lymphocytes Cancer Res., November 1, 2000; 60(22): 6272 - 6275. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
